APA
Click to copy
Gabrielli, L., García, L., Fernández, R., Vega, J., Ocaranza, M., Contreras, F., … Sitges, M. (2019). P4421Increased circulating levels of VCAM-1 correlate with left atrial remodeling in highly trained athletes. European Heart Journal.
Chicago/Turabian
Click to copy
Gabrielli, L., Lorena García, R. Fernández, J. Vega, M. Ocaranza, F. Contreras, Manuel Salinas, et al. “P4421Increased Circulating Levels of VCAM-1 Correlate with Left Atrial Remodeling in Highly Trained Athletes.” European Heart Journal (2019).
MLA
Click to copy
Gabrielli, L., et al. “P4421Increased Circulating Levels of VCAM-1 Correlate with Left Atrial Remodeling in Highly Trained Athletes.” European Heart Journal, 2019.
BibTeX Click to copy
@article{l2019a,
title = {P4421Increased circulating levels of VCAM-1 correlate with left atrial remodeling in highly trained athletes},
year = {2019},
journal = {European Heart Journal},
author = {Gabrielli, L. and García, Lorena and Fernández, R. and Vega, J. and Ocaranza, M. and Contreras, F. and Salinas, Manuel and Chiong, M. and Jalil, J. and Muñoz, M. C. and Yáñez, F. and Lavandero, S. and Castro, P. and Sitges, M.}
}
Reports have shown increased risk of atrial fibrillation (AF) in athletes. Vascular cell adhesion molecule-1 (VCAM1) is associated with new onset AF in general population. VCAM1 and its relation with left atrial (LA) remodeling have not been investigated in athletes.
To study VCAM1 and LA remodeling in marathon runners.
Study of 36 male marathon runners in the training period previous to race (42 km) and 18 sedentary controls with no risk factors. Athletes were divided in two groups according to highest training intensity reached (group 1, >100 km/week; group 2, 50–100 km/week). Previous to race in all subjects, VCAM1 serum levels were measured by ELISA and an echocardiogram was performed. In athletes, VCAM1 was measured immediately post-race. Wilcoxon and Spearman were used.
See table. Group 1 showed a significant increment in VCAM1 post-race (651±350 to 905±373 ng/mL; p=0.002) as compared to group 2 with no increment (533±133 to 651±138 ng/mL; p=0.117). In athletes, a moderate correlation between LA volume and VCAM1 was found (rho: 0.483; p=0.007). Baseline characteristics Group 1 (n=18) Group 2 (n=18) Controls (n=18) p value Age (years) 37±6 38±5 36±4 0.373 Heart rate (bpm) 53±8 57±7 69±6 * 0.001 Body surface area (m2) 1.8±0.1 1.8±0.1 1.9±0.1 0.075 LV diastolic diameter (mm) 49±5 48±5 46±4 0.404 LV systolic diameter (mm) 29±5 30±5 30±4 0.879 Septal wall (mm) 9.1±1.2† 8.2±1.1 8.1±0.8 0.005 Posterior wall (mm) 9.3±2.1† 8.5±1.2 7.6±0.8 0.001 Ejection fraction (%) 55±3 55±6 57±4 0.110 LV mass index (g/m2) 106±27† 78±18 58±11 0.001 LA volume (mL/m2) 42±8† 30±11 25±9 0.001 E wave (cm/sec) 78±13 84±12 77±15 0.217 A wave (cm/sec) 50±12 53±10 48±16 0.438 DT (msec) 233±65 229±65 221±66 0.184 VCAM1 (ng/mL) 651±350† 533±133 440±98 0.022 Mean ± SD. *p<0.05 vs group 1 and 2 post Kruskall-Wallis; †p<0.05 vs other groups post Kruskall-Wallis. LV, left ventricle; LA, left atrium; DT, deceleration time.
Most trained athletes had increased levels of VCAM1 as compared to controls and less trained athletes. They also showed an increment post-effort. VCAM1 is related to LA remodeling in athletes. VCAM1 could be a potential biomarker of AF in athletes which should be confirmed.
FONDECYT 1170963 (LG); FONDAP 15130011 (LG,SL)